PMID- 8655288
OWN - NLM
STAT- MEDLINE
DCOM- 19960801
LR  - 20190920
IS  - 0162-3109 (Print)
IS  - 0162-3109 (Linking)
VI  - 31
IP  - 1
DP  - 1995 Nov
TI  - Methylxanthines with adenosine alter TNF alpha-primed PMN activation.
PG  - 19-29
AB  - Methylxanthines are best known as phosphodiesterase inhibitors that cause a rise 
      in intracellular cAMP. One would expect the two methylxanthines, caffeine and 
      pentoxifylline, to have similar actions on neutrophils (PMN). However, caffeine 
      stimulated and pentoxifylline inhibited PMN oxidative activity. Micromolar 
      concentrations of pentoxifylline decreased native and recombinant tumor necrosis 
      factor-alpha (TNF alpha)-primed formyl met-leu-phe (fMLP)-stimulated PMN 
      chemiluminescence, superoxide production and myeloperoxidase (MPO) release. In 
      contrast, equal concentrations of caffeine increased chemiluminescence and MPO 
      release with no effect on superoxide production. These activities of the 
      methylxanthines were only observed in the presence of physiological 
      concentrations of adenosine, and were abolished by the treatment of the PMN with 
      adenosine deaminase. The activities of adenosine, pentoxifylline and caffeine on 
      PMN activity could not be readily explained by changes in PMN [cAMP]. Thus for 
      TNF alpha-primed PMN, pentoxifylline decreases PMN activity by enhancing the 
      effect of adenosine on degranulation and superoxide production; whereas caffeine 
      increases PMN activity by counteracting the effect of adenosine on degranulation.
FAU - Sullivan, G W
AU  - Sullivan GW
AD  - Department of Medicine, University of Virginia, Charlottesville 22908, USA.
FAU - Luong, L S
AU  - Luong LS
FAU - Carper, H T
AU  - Carper HT
FAU - Barnes, R C
AU  - Barnes RC
FAU - Mandell, G L
AU  - Mandell GL
LA  - eng
GR  - AI09504/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Immunopharmacology
JT  - Immunopharmacology
JID - 7902474
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11062-77-4 (Superoxides)
RN  - 3G6A5W338E (Caffeine)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - K72T3FS567 (Adenosine)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Adenosine/*pharmacology
MH  - Caffeine/*pharmacology
MH  - Humans
MH  - Kinetics
MH  - Luminescent Measurements
MH  - *Neutrophil Activation
MH  - Neutrophils/*drug effects/*metabolism
MH  - Pentoxifylline/*pharmacology
MH  - Peroxidase/metabolism
MH  - Superoxides/metabolism
MH  - Tumor Necrosis Factor-alpha/immunology
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 0162310995000300 [pii]
AID - 10.1016/0162-3109(95)00030-0 [doi]
PST - ppublish
SO  - Immunopharmacology. 1995 Nov;31(1):19-29. doi: 10.1016/0162-3109(95)00030-0.